Novavax Inc Stock Price, News & Analysis

Novavax (Nasdaq: NVAX) announced its involvement in the Phase 2 Com-COV3 clinical trial led by the University of Oxford, aimed at evaluating mixed COVID-19 vaccine schedules in adolescents aged 12-16. The trial will involve at least 360 participants receiving initial doses of authorized vaccines followed by a second dose of either the same or a different vaccine, including NVX-CoV2373. Results are anticipated within months, contributing to flexible vaccination strategies.

Novavax, a biotechnology company, announced participation in two investor conferences. The discussions will center around its recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373. The first event is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, featuring a fireside chat and a panel on pandemic planning. The second is the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021. Replays of the sessions will be available on Novavax's events page.

Novavax, Inc. (Nasdaq: NVAX) has enrolled the first participants in a Phase 1/2 study assessing the safety and immunogenicity of a combined vaccine for COVID-19 and seasonal influenza. This innovative COVID-NanoFlu Combination Vaccine utilizes Novavax' recombinant protein-based NVX-CoV2373 and NanoFlu™ candidates, enhanced by the Matrix-M™ adjuvant. The trial, set to involve 640 healthy adults aged 50 to 70, will take place across Australia, with results anticipated in the first half of 2022.

Novavax, a biotechnology company focused on next-generation vaccines, announced its participation in Citi's 16th Annual BioPharma Virtual Conference on September 9, 2021. The event will feature a fireside chat discussing Novavax' COVID-19 vaccine candidate, NVX-CoV2373. Key participants from Novavax, including Dr. Gregory M. Glenn and John J. Trizzino, will represent the company. A replay of the session will be available on Novavax's website for 90 days following the event.

The company continues its late-stage trials for NVX-CoV2373 and its influenza vaccine, NanoFlu.

Novavax, Inc. (Nasdaq: NVAX) announced that the CDC has updated guidance stating participants in the PREVENT-19 Phase 3 clinical trial can be considered fully vaccinated two weeks after completing the vaccine series. This recognition underscores the efficacy of Novavax's vaccine candidate, NVX-CoV2373, which demonstrated 90% overall efficacy and 100% protection against moderate and severe disease in the trial. The update ensures clarity for trial participants, highlighting their contributions to public health despite the vaccine's non-authorization by the FDA.

Novavax (Nasdaq: NVAX) has initiated the OCTAVE-DUO study in the UK to assess the safety and efficacy of a third COVID-19 vaccine dose for immunocompromised individuals. This study, funded by the UK government's Vaccines Taskforce, includes 320 participants with lymphoid malignancies who previously showed low or no response to two doses of a primary vaccine. One-third will receive Novavax's NVX-CoV2373 vaccine. Results are expected later in 2021, aiding insights into vaccination strategies for vulnerable populations.

On August 16, 2021, Novavax, Inc. (Nasdaq: NVAX) announced the appointment of Jim Kelly as Executive Vice President and Chief Financial Officer, and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance. Jim Kelly brings over 25 years of experience, previously serving as CFO at Supernus Pharmaceuticals and Vanda Pharmaceuticals. Nasir Egal, with extensive quality experience from Sanofi and Merck, will enhance Novavax's regulatory and commercial activities, particularly for its COVID-19 vaccine. This leadership change is aimed at strengthening Novavax's operational capabilities in the global vaccine market.

Novavax (NVAX) reported a significant net loss of $352 million for Q2 2021, translating to $4.75 per share, compared to a loss of $18 million in Q2 2020. Revenue surged to $298 million from $36 million, driven by development activities for NVX-CoV2373. R&D expenses skyrocketed to $571 million, up from $35 million year-over-year. The company holds $2.1 billion in cash as of June 30, 2021, facilitating ongoing vaccine development and regulatory submissions globally. Key vaccine advancements include 90.4% efficacy in the Phase 3 trial and plans to file for emergency authorizations in several markets.

Novavax (Nasdaq: NVAX) announced promising preliminary data from a Phase 2 study revealing that a single booster dose of its NVX-CoV2373 COVID-19 vaccine, administered six months after initial vaccination, resulted in a 4.6-fold increase in functional antibody titers. Additionally, the booster elicited a more than six-fold increase in antibodies against the Delta variant. The study underscored a favorable safety profile, with side effects primarily mild and transient. The full data will be submitted for peer review.